University of Southern Denmark
Odense, Region Syddanmark, 5000, Denmark
NCT Number: NCT05073627
Worldwide there is an increase in antibiotic resistance which may have fatal long-term consequences. This is due to extensive use and sometimes misuse of antibiotics in the treatment of harmless infections.
The primary aim of this study is to investigate if treatment with dicloxacillin can lead to drug-drug interactions through induction of the efflux transporter P-glycoprotein (P-gp). In this study it will also be investigated whether dicloxacillin induces its own metabolism.
The hypothesis is based on a previous in vivo study showing that rifampicin induces the intestinal P-gp transporter, through activation of the pregnane X receptor (PXR). Dicloxacillin also activates the PXR receptor in vitro, which could result in an induction of P-gp in vivo.
Trial subjects will ingest dicloxacillin for 30 days and at day 10 and 28 ingest dabigatran etexilate to determine if the P-gp transporter has been induced. Plasma and urine will be drawn over 32 hours to determine the concentration of dabigatran.
Change in dicloxacillin concentration will also be measured at day 9 and 27 to establish if dicloxacillin induces its own metabolism.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Odense, Region Syddanmark, 5000, Denmark
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Anticoagulants, antiplatelet aggregation medicinal products, ticagrelor, clopidogrel, acetylsalicylic acid, chronic NSAIDs use, amiodarone, verapamil, systemic ketoconazole, clarithromycin, cyclosporin, itraconazole, tacrolimus, posaconazole, dronedarone, glecaprevir/pibrentasvir, quinidine, ritonavir, digoxin, selective serotonin reuptake inhibitors (SSRIs), selective serotonin norephinephrine reuptake inhibitors (SNRIs), pantoprazole, ranitidine, previous use of dicloxacillin or other P-gp or Cytochrome P450 (CYP450) inhibitors/inducers within 4 weeks prior to the start of treatment, probenecid, tetracycline, methotrexate
Mechanical heart valve, congenital or acquired coagulation disorders, thrombocytopenia or functional platelet defects, biopsy within 4 weeks, major trauma, bacterial endocarditis, esophagitis, gastritis, gastroesophageal reflux, active meningitis, encephalitis, intracranial abscess, undergoing surgery, liver disease, history of thrombosis or diagnosed with antiphospholipid syndrome, active cancer
Healthy volunteers will take 2x500 mg dicloxacillin 3 times a day for 30 days. The investigators will measure the baseline concentration of dabigatran and dicloxacillin before start of 30 days of dicloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of dicloxacillin. On day 10 and 28 the investigators will measure the concentration of dabigatran.
Other names: Dabigatran etexilate
Time frame: Baseline and day 28
Change in the activity of the drug transporter P-gp
Time frame: Day 10 and 28
Change in the activity of the drug transporter P-gp
Time frame: Day 10 and 28
Change in the activity of the drug transporter P-gp
Time frame: Day 10 and 28
Change in the activity of the drug transporter P-gp
Time frame: Day 10 and 28
Change in the activity of the drug transporter P-gp
Time frame: Day 10 and 28
Change in the activity of the drug transporter P-gp
Time frame: Day 10 and 28
Change in the activity of the drug transporter P-gp
Time frame: Day 10 and 28
Change in the activity of the drug transporter P-gp
Time frame: Day 10 and 28
Change in the activity of the drug transporter P-gp
Time frame: Day 10 and 28
Change in the activity of the drug transporter P-gp
Time frame: Day 10 and 28
Change in the activity of the drug transporter P-gp
Time frame: Day 9 and 27
Change in the activity of the enzyme responsible for metabolism of dicloxacillin
Time frame: Day 9 and 27
Change in the activity of the enzyme responsible for metabolism of dicloxacillin
Time frame: Day 9 and 27
Change in the activity of the enzyme responsible for metabolism of dicloxacillin
Time frame: Day 9 and 27
Change in the activity of the enzyme responsible for metabolism of dicloxacillin
Time frame: Day 9 and 27
Change in the activity of the enzyme responsible for metabolism of dicloxacillin
Time frame: Day 9 and 27
Change in the activity of the enzyme responsible for metabolism of dicloxacillin
Time frame: Day 9 and 27
Change in the activity of the enzyme responsible for metabolism of dicloxacillin
Time frame: Day 9 and 27
Change in the activity of the enzyme responsible for metabolism of dicloxacillin
Time frame: Day 9 and 27
Change in the activity of the enzyme responsible for metabolism of dicloxacillin
Time frame: Day 9 and 27
Change in the activity of the enzyme responsible for metabolism of dicloxacillin
Time frame: 10 and 28
Change in biomarkers for enzymes and transporters after dicloxacillin treatment
Time frame: 10 and 28
Change in exosome-derived biomarkers after dicloxacillin treatment to determine activity of CYP enzymes
University of Southern Denmark
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01361217
Drug-drug Interaction, Healthy Volunteers
View Trial DetailsNCT01309854
Amount of Pioglitazone in Blood, Arthritis
Overland Park, Kansas, United States
View Trial DetailsNCT05447078
Healthy Volunteers, Infections
Jackson, Mississippi, United States
View Trial DetailsNCT07513532
Healthy Volunteers
Seattle, Washington, United States
View Trial Details